9E
9EH.F Evolent Health Inc
- Market cap
- EUR 482M
- P/E
- -
- P/B
- 1.41x
- ROE
- -28.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 9EH.F undervalued?
Graham numberThe Graham number of Evolent Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evolent Health Inc fundamental analysis
No fundamental analysis for Evolent Health Inc yet.
Evolent Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evolent Health Inc
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technolo…
Full company profileEvolent Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evolent Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 254M | 435M | 627M | 846M | 1.02B | 908M | 1.35B | 1.96B | 2.55B | 1.88B | 2.50B |
| Gross Profit | 99.0M | 166M | 299M | 333M | 321M | 250M | 317M | 460M | 367M | 400M | 337M |
| Operating Income | -78.9M | -72.4M | -51.6M | -120M | -51.0M | -29.1M | -19.9M | -21.1M | -14.1M | -19.8M | -35.1M |
| EBITDA | - | -40.4M | -4.15M | -252M | -248M | 55.7M | 20.7M | -24.8M | 80.1M | -361M | 47.4M |
| Net Income | -160M | -60.7M | -52.7M | -302M | -334M | -37.6M | -19.2M | -113M | -61.6M | -535M | -105M |
| EPS | - | -0.78 | -0.64 | -3.57 | -3.96 | -0.42 | -0.19 | -0.99 | -0.54 | -4.79 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 1.20B | 1.31B | 1.72B | 1.50B | 1.37B | 1.42B | 1.82B | 2.68B | 2.54B | 1.90B | 1.96B |
| Total Liabilities | 288M | 266M | 533M | 569M | 751M | 726M | 958M | 1.61B | 1.54B | 1.48B | 1.59B |
| Shareholders' Equity | 703M | 1.01B | 1.14B | 922M | 620M | 694M | 859M | 1.07B | 1.00B | 415M | 373M |
| Cash & Short-term Investments | 135M | 238M | 228M | 101M | 340M | 266M | 188M | 193M | 104M | 152M | 148M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.5M | -28.0M | -20.7M | -42.6M | -16.2M | 38.7M | -11.6M | 88.9M | 18.8M | 38.8M | 21.4M |
| Capital Expenditure | 15.5M | 27.8M | 170M | 44.1M | 32.1M | 27.5M | 296M | 33.4M | 24.9M | 34.1M | 27.3M |
| Free Cash Flow | - | -55.8M | -60.2M | -78.2M | -45.7M | 38.7M | -11.6M | 55.5M | -6.13M | 4.76M | -5.84M |
| Ratios | |||||||||||
| ROE | -22.7% | -6.0% | -4.6% | -32.7% | -53.9% | -5.4% | -2.2% | -10.6% | -6.2% | -128.7% | -28.1% |
| ROA | -13.3% | -4.6% | -3.1% | -20.2% | -24.4% | -2.6% | -1.1% | -4.2% | -2.4% | -28.1% | -5.3% |
| Net Profit Margin | -62.8% | -13.9% | -8.4% | -35.7% | -32.7% | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% | -4.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Evolent Health Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 11.1M | 0.10 | - |
| 2024 | USD 20.1M | 0.17 | - |
| 2023 | USD 13.6M | 0.12 | - |
| 2022 | USD 14.9M | 0.15 | - |
| 2021 | USD 1.30M | 0.01 | - |
| 2020 | USD 20.0M | 0.24 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Evolent Health Inc
- Insiders 3.10%
- Institutions 96.90%
- Public & others 0.00%
- Shares outstanding 113M
- Free float 94.3M
Evolent Health Inc company profile
- Company name
- Evolent Health Inc
- Ticker
- 9EH.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 4,200
- Fiscal year end
- December
- Address
- 1812 N. Moore Street, Arlington, VA, United States, 22209
- Phone
- 571 389 6000
- Website
- evolent.com
About Evolent Health Inc
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Evolent Health Inc management
10- Mr. Seth Barrie BlackleyCo-Founder, CEO & Director · born 1979
- Mr. Dan McCarthyPresident · born 1985
- Mr. Jonathan David Weinberg J.D.Chief Legal Officer, General Counsel & Secretary · born 1968
- Mr. John Paul JohnsonChief Strategy Officer · born 1984
- Mr. Mario Marques RamosChief Financial Officer · born 1972
- Ms. Katie DiPerna CookChief Operating Officer
- Mr. Aammaad ShamsChief Accounting Officer · born 1984
- Mr. Robert CruzChief Technology Officer
- Ms. Jessica WhiteChief Information Officer
- Dr. John Tam M.D.Chief Growth Officer